On Tuesday, March 29, 2016, the Psychopharmacologic Drugs Advisory Committee (PDAC) supported, by a vote of 12-Yes to 2-No, with no abstentions, the safety and efficacy of Nuplazid (pimavanserin), submitted by Acadia Pharmaceuticals Inc. (Acadia) for the proposed treatment of psychosis associated with Parkinson's disease. The PDUFA date for pimavanserin is May 1, 2016.